SK Bioscience Co Ltd (302440) - Total Assets
Based on the latest financial reports, SK Bioscience Co Ltd (302440) holds total assets worth ₩2.92 Trillion KRW (≈ $1.98 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SK Bioscience Co Ltd - Total Assets Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see SK Bioscience Co Ltd stock valuation for the company's overall valuation and market capitalisation.
SK Bioscience Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
SK Bioscience Co Ltd's total assets of ₩2.92 Trillion consist of 55.5% current assets and 44.6% non-current assets. Review debt load of SK Bioscience Co Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 11.0% |
| Accounts Receivable | ₩94.46 Billion | 3.3% |
| Inventory | ₩211.13 Billion | 7.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩67.11 Billion | 2.4% |
| Goodwill | ₩57.44 Billion | 2.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SK Bioscience Co Ltd (302440) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SK Bioscience Co Ltd's current assets represent 55.5% of total assets in 2024, an increase from 44.9% in 2018.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2024, up from 1.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 5.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 7.4% of total assets.
SK Bioscience Co Ltd Competitors by Total Assets
Key competitors of SK Bioscience Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $715.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
USA | $470.43 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
CureVac NV
F:5CV
|
Germany | €1.14 Billion |
SK Bioscience Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.27 | 11.69 | 1.85 |
| Quick Ratio | 3.58 | 10.86 | 1.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩1.05 Trillion | ₩1.37 Trillion | ₩153.26 Billion |
SK Bioscience Co Ltd - Advanced Valuation Insights
This section examines the relationship between SK Bioscience Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 53.5% |
| Total Assets | ₩2.84 Trillion |
| Market Capitalization | $1.90 Billion USD |
Valuation Analysis
Below Book Valuation: The market values SK Bioscience Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SK Bioscience Co Ltd's assets grew by 53.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual total assets of SK Bioscience Co Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.84 Trillion ≈ $1.93 Billion |
+53.51% |
| 2023-12-31 | ₩1.85 Trillion ≈ $1.26 Billion |
-13.52% |
| 2022-12-31 | ₩2.14 Trillion ≈ $1.45 Billion |
+1.51% |
| 2021-12-31 | ₩2.11 Trillion ≈ $1.43 Billion |
+275.31% |
| 2020-12-31 | ₩562.23 Billion ≈ $381.02 Million |
+39.17% |
| 2019-12-31 | ₩403.98 Billion ≈ $273.77 Million |
+0.31% |
| 2018-12-31 | ₩402.71 Billion ≈ $272.91 Million |
-- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more